EP4267108A4 - Arn autorépliquant et utilisations associées - Google Patents

Arn autorépliquant et utilisations associées

Info

Publication number
EP4267108A4
EP4267108A4 EP22920982.0A EP22920982A EP4267108A4 EP 4267108 A4 EP4267108 A4 EP 4267108A4 EP 22920982 A EP22920982 A EP 22920982A EP 4267108 A4 EP4267108 A4 EP 4267108A4
Authority
EP
European Patent Office
Prior art keywords
self
replicated rna
replicated
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22920982.0A
Other languages
German (de)
English (en)
Other versions
EP4267108A1 (fr
Inventor
Pirada ALLEN
Ivna DE SOUZA
Yingxia Wen
Cheng Chang
Changkeun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seqirus Inc
Original Assignee
Seqirus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus Inc filed Critical Seqirus Inc
Priority to EP25180249.2A priority Critical patent/EP4711458A3/fr
Publication of EP4267108A1 publication Critical patent/EP4267108A1/fr
Publication of EP4267108A4 publication Critical patent/EP4267108A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
EP22920982.0A 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées Withdrawn EP4267108A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25180249.2A EP4711458A3 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/051021 WO2023148527A1 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25180249.2A Division EP4711458A3 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées

Publications (2)

Publication Number Publication Date
EP4267108A1 EP4267108A1 (fr) 2023-11-01
EP4267108A4 true EP4267108A4 (fr) 2025-02-12

Family

ID=87553205

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22920982.0A Withdrawn EP4267108A4 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées
EP25180249.2A Pending EP4711458A3 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP25180249.2A Pending EP4711458A3 (fr) 2022-02-07 2022-02-07 Arn autorépliquant et utilisations associées

Country Status (8)

Country Link
EP (2) EP4267108A4 (fr)
JP (1) JP2025507234A (fr)
KR (1) KR20240139971A (fr)
CN (1) CN116916891A (fr)
BR (1) BR112023015660A2 (fr)
CA (1) CA3207885A1 (fr)
IL (1) IL304699A (fr)
WO (1) WO2023148527A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191630A1 (fr) * 2020-03-27 2021-09-30 Imperial College Innovations Limited Vaccin contre un coronavirus
WO2021229450A1 (fr) * 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Vaccins contre le sars-cov-2
WO2021255270A1 (fr) * 2020-06-19 2021-12-23 Ziphius Vaccines Vaccin à arn contre le sars-cov-2 à auto-amplification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3018416T3 (es) * 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
KR20230009489A (ko) * 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
CN113185613B (zh) * 2021-04-13 2022-09-13 武汉大学 新型冠状病毒s蛋白及其亚单位疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191630A1 (fr) * 2020-03-27 2021-09-30 Imperial College Innovations Limited Vaccin contre un coronavirus
WO2021229450A1 (fr) * 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Vaccins contre le sars-cov-2
WO2021255270A1 (fr) * 2020-06-19 2021-12-23 Ziphius Vaccines Vaccin à arn contre le sars-cov-2 à auto-amplification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOM KRISTIE ET AL: "Self-amplifying RNA vaccines for infectious diseases", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 28, no. 3-4, 22 October 2020 (2020-10-22), pages 117 - 129, XP037440972, ISSN: 0969-7128, [retrieved on 20201022], DOI: 10.1038/S41434-020-00204-Y *
See also references of WO2023148527A1 *

Also Published As

Publication number Publication date
EP4711458A2 (fr) 2026-03-18
WO2023148527A1 (fr) 2023-08-10
KR20240139971A (ko) 2024-09-24
EP4711458A3 (fr) 2026-05-27
IL304699A (en) 2023-09-01
CN116916891A (zh) 2023-10-20
JP2025507234A (ja) 2025-03-18
BR112023015660A2 (pt) 2023-10-24
CA3207885A1 (fr) 2023-08-07
EP4267108A1 (fr) 2023-11-01

Similar Documents

Publication Publication Date Title
EP4117682C0 (fr) Nucléotides modifiés et leurs utilisations
EP4444290A4 (fr) Agents de dégradation de stat3 et leurs utilisations
EP4085076C0 (fr) Anticorps se liant à bcma et leurs utilisations
EP4159738A4 (fr) Inhibiteur de jak macrocyclique et ses utilisations
EP4262883C0 (fr) Lipides peg et nanoparticules lipidiques
EP4437094A4 (fr) Nucléases iscb reprogrammables et leurs utilisations
EP4430035A4 (fr) Inhibiteurs de kras g12c sélectionnés et leurs utilisations
EP4359442A4 (fr) Anticorps anti-ccr8 et leurs utilisations
EP4182351A4 (fr) Molécules de liaison à cd19 et leurs utilisations
EP4244255A4 (fr) Anticorps anti-tigit et leurs utilisations
EP4142793A4 (fr) Anticorps spécifiques à abcb5 et leurs utilisations
EP4126938A4 (fr) Anticorps se liant à siglec15 et leurs utilisations
EP4504190A4 (fr) Inhibiteurs d'oxadiazole hdac6 et leurs utilisations
EP4395822A4 (fr) Anticorps anti-acvr2a et leurs utilisations
EP4247419A4 (fr) Anticorps anti-marco et utilisations associées
EP4396224A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP4146272A4 (fr) Anticorps anti-covid-19 et leurs utilisations
EP4106813A4 (fr) Molécules de liaison à cd137 et leurs utilisations
EP4493540A4 (fr) Promédicaments de ralinepag et leurs utilisations
EP4444744A4 (fr) Système de dégradation de microvésicules à médiation par arrdc1 (armm) et ses utilisations
EP4373856A4 (fr) Anticorps anti-cll-1 et leurs utilisations
EP4263612A4 (fr) Molécules de liaison à la mésothéline et leurs utilisations
EP4263615A4 (fr) Molécules de liaison à gucy2c et leurs utilisations
EP4198040C0 (fr) Complexe pt-dpephos-iode et complexe pt-dpephos-brome
EP4244205A4 (fr) Inhibiteurs d'ire1alpha et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092973

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20241014BHEP

Ipc: C07H 21/04 20060101ALI20241014BHEP

Ipc: C12N 15/00 20060101ALI20241014BHEP

Ipc: A61K 39/12 20060101ALI20241014BHEP

Ipc: A61K 39/215 20060101ALI20241014BHEP

Ipc: A61K 48/00 20060101ALI20241014BHEP

Ipc: A61K 9/127 20060101AFI20241014BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250113

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20250107BHEP

Ipc: C07H 21/04 20060101ALI20250107BHEP

Ipc: C12N 15/00 20060101ALI20250107BHEP

Ipc: A61K 39/12 20060101ALI20250107BHEP

Ipc: A61K 39/215 20060101ALI20250107BHEP

Ipc: A61K 48/00 20060101ALI20250107BHEP

Ipc: A61K 9/127 20060101AFI20250107BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250731